search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
THE POWER OF PREEMPTION


OMIDRIA® is the first and only


FDA-approved drug that provides continuous intracameral delivery


of NSAID and mydriatic/anti-miotic therapy during cataract surgery1


Coming October 1, 2018—Reinstatement of separate payment under Medicare Part B extends the benefit of OMIDRIA to more patients.


• Beginning October 1, 2018, OMIDRIA use in cataract and lens replacement surgery for patients with Medicare Part B coverage will be separately reimbursed for an additional 2 years


INDICATIONS AND USAGE


OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.


IMPORTANT SAFETY INFORMATION OMIDRIA must be added to irrigating solution prior to intraocular use. OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure.


Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.


The most commonly reported adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.


Please see the Full Prescribing Information for OMIDRIA at www.omidria.com/prescribinginformation.


You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Reference: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017.


Visit www.omidria.com


Omeros does not guarantee reimbursement by any third-party payer. To be eligible for the “Equal Access” Patient Assistance Program, patients must be enrolled in OMIDRIAssure prior to surgery. For any patient for whom your facility received a free vial through the “Equal Access” Patient Assistance Program, the patient’s insurance carrier(s) should not be billed for OMIDRIA. OMIDRIAssure program services are subject to change without notice.


OMEROS®, the OMEROS logo®, OMIDRIA®, the OMIDRIA logo®, and OMIDRIAssure® are registered trademarks of Omeros Corporation.


© Omeros Corporation 2018, all rights reserved. 2018-013


• Centers for Medicare & Medicaid Services (CMS) reimbursement will be managed under the same procedures that were in effect through 2017


• Omeros continues to support access to OMIDRIA through the OMIDRIAssure® Patient Assistance Program


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48